PRL secreting adenomas in male patients

被引：42

作者：

Ciccarelli A. ^{[1
]}

Guerra E. ^{[1
]}

Rosa M. ^{[1
]}

Milone F. ^{[1
]}

Zarrilli S. ^{[1
]}

Lombardi G. ^{[1
]}

Colao A. ^{[1
]}

机构：

[1] Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, 80131 Naples

来源：

Pituitary | 2005年 / 8卷 / 1期

关键词：

Cabergoline; Dopamine; Male fertility; Prolactin; Prolactinomas; Seminal fluid; Spermatozoa;

D O I：

10.1007/s11102-005-5084-3

中图分类号：

学科分类号：

摘要：

Prolactinomas are the most frequent pituitary tumors and their frequency varies with age and sex, occurring most frequently in females between 20-50 yr-old. In men, hyperprolactinaemia is often present for many years without symptoms, as generally the most important symptoms are the decrease in libido and/or sexual potency both underestimated by the majority of the patients. Prolactin (PRL) plays a role in the process of spermatogenesis, and normal serum PRL levels are required for normal testicular function. On the other hand, hyperprolactinaemia has multiple negative effects on the gonadal axis. As a consequences hyperprolactinemic males show alteration of sexual potency and seminal fluid quality. Cabergoline treatments is able to induce normalization of PRL levels and a reduction of tumor mass in the majority of patients and consequently restoring the normal semen quality and ameliorating the quality of life of men with pituitary PRL-secreting adenoma. © Springer Science + Business Media, Inc. 2005.

引用

页码：39 / 42

页数：3

共 20 条

[1] Colao A., Lombardi G., Growth-hormone and prolactin excess, Lancet, 352, pp. 1455-1461, (1998)
[2] Colao A., Di Sarno A., Cappabianca P., Et al., Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia, Eur J Endocrinol, 148, 3, pp. 325-331, (2003)
[3] Vance M.L., Thorner M.O., Prolactin: Hyperprolactinemic syndromes and management, Textbook of Endocrinology, pp. 408-418, (1989)
[4] Calle-Rodrigue R.D., Giannini C., Scheithauer B.W., Et al., Prolactinomas in male and female patients: A comparative clinicopathologic study, Mayo Clin Proc, 73, pp. 1046-1052, (1998)
[5] Delgrange E., Trouillas J., Maiter D., Donckier J., Tourniaire J., Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study, J Clin Endocrinol Metab, 82, pp. 2102-2107, (1997)
[6] Verhelst J., Abs R., Maiter D., Et al., Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients, J Clin Endocrinol Metab, 84, 7, pp. 2518-2522, (1999)
[7] Molitch M.E., Prolactinoma, The Pituitary, pp. 443-477, (1995)
[8] Leonard M.P., Nickel C.J., Marales A., Hyperprolactinemia and impotence: Why, when and how to investigate, J Urol, 142, 4, pp. 992-994, (1989)
[9] Colao A., Vitale G., Cappabianca P., Et al., Outcome of Cabergoline treatment in men with prolactinoma: Effects of a 24-months treatment on prolactin levels, tumor mass, recovery of pituitari function, and semen analysis, J Clin Endocrinol Metab, 89, pp. 1704-1711, (2004)
[10] Biller B.M.K., Molitch M., Vance M.L., Et al., Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline, J Clin Endocrinol Metab, 81, 6, pp. 2338-2343, (1996)

← 1 2 →